- $368.55m
- $326.71m
- $79.18m
Simulations Plus Inc expected to post earnings of 18 cents a share - Earnings Preview
Simulations Plus Inc reports results for the quarter ended in May - Earnings Summary
Brief: Simulations Plus Q3 Revenue USD 16.2 Million
Simulations Plus Inc expected to post earnings of 20 cents a share - Earnings Preview
Brief: Simulations Plus Acquires Immunetrics To Expand Its Immunology And Oncology Drug Development Capabilities
Brief: Simulations Plus Receives U.S. FDA Renewal For Dilisym Software Licenses
Simulations Plus Inc reports results for the quarter ended in February - Earnings Summary
Brief: Simulations Plus Reports Q2 Revenue of USD 15.8 Million
Brief: Simulations Plus Reports Second Quarter Results
Simulations Plus Inc expected to post earnings of 18 cents a share - Earnings Preview
Brief: Simulations Plus Enters New Strategic Collaboration To Discover Anticancer Therapies Through Its Ai-Driven Drug Design Technology
Brief: Simulations Plus Enters Partnership To Apply AI/ML Technologies To Design Novel Compounds
Brief: Simulations Plus Executes $20 Mln Accelerated Share Repurchase Agreement
Simulations Plus Inc reports results for the quarter ended in November - Earnings Summary
Brief: Simulations Plus Reports Q1 Fiscal 2023 Financial Results
Simulations Plus Inc expected to post earnings of 9cents a share - Earnings Preview
Simulations Plus Inc reports results for the quarter ended in August - Earnings Summary
Brief: Simulations Plus Says Qtrly Total Revenue Increased 19% To $11.7 Mln
Simulations Plus Inc expected to post earnings of 7cents a share - Earnings Preview